Immunopathogenesis of Systemic Lupus Erythematosus Publisher



Akhtari M^{1, 2} ; Farhadi E^{1, 2} ; Mahmoudi M^{1, 2} Show Affiliations
Source: Translational Autoimmunity: Volume 6: Advances in Autoimmune Rheumatic Diseases Published:2023

Abstract

Systemic lupus erythematosus (SLE) is a debilitating chronic autoimmune disease that affects almost all organs and tissues in the body. It has been more than 100years since SLE was recognized and defined as a multisystem disease with apparent autoimmune involvements. However, the exact pathophysiology of SLE remains unclear, and the effective treatments are under investigation. Due to the development of diagnostic tools, the discovery of immunosuppressive and biologic therapies, and the availability of supportive efficient treatment for infectious and renal involvement, the prognosis of the disease improved. However, patients with SLE show increased mortality rates of about two or four times more than healthy individuals. The immunopathogenesis of SLE has been deeply considered during the past decades. In this chapter, we highlighted a number of important aspects of the pathogenesis of SLE and discussed different new molecular pathways that can be used as a new target to treat the disease. Due to the diverse and heterogeneous clinical manifestations in SLE patients, it is suggested that targeting more than one pathway and using specified and personalized therapy could have beneficial outcomes in patient’s treatment. © 2023 Elsevier Inc. All rights reserved.